MGX · Metagenomi Therapeutics, Inc.
Market Cap
$44.95M
Shares
37.78M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2025-03-17 | — | $75,000,000 | — | — | 10-Q , filed 2026-08-10 |
Key facts
CIK
1785279
CUSIP
59102M104
13F (30d)
40 filings
40 filers
Visit website
Investor relations